BioStock: Aptahem on the latest news

Aptahem has communicated several positive news lately. Recently, the company received patent protection in Japan for patent family 2 regarding the drug candidate Apta-1. Encouraging data from research on treatment with Apta-1 in a coronavirus-induced lung injury model was also published, followed by the news that the GMP production of Apta-1 has been completed. BioStock contacted CEO Mikael Lindstam for a comment.

Read the full interview with Mikael Lindstam at biostock.se:

https://www.biostock.se/en/2022/03/aptahem-on-the-latest-news/

This is a press release from BioStock - Connecting Innovation & Capital. https://www.biostock.se/